SI1527047T1 - z N metil piperazin il metilkarbonil N metil amino anilino fenil metilen metoksikarbonil indolinon monoetansulfonat in njegova uporaba kot farmacevtski sestavek - Google Patents

z N metil piperazin il metilkarbonil N metil amino anilino fenil metilen metoksikarbonil indolinon monoetansulfonat in njegova uporaba kot farmacevtski sestavek

Info

Publication number: SI1527047T1
Authority: SI; Slovenia
Prior art keywords: methyl; methylcarbonyl; methoxycarbonyl; pharmaceutical composition; phenyl methylene
Prior art date: 2002-07-24

Application number

SI200332162T

Other languages

English (en)

Inventor

Gerald Jurgen Roth

Peter Sieger

Guenter Linz

Werner Rall

Frank Hilberg

Thomas Bock

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-24

Filing date

2003-07-18

Publication date

2012-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1527047(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-18 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2012-07-31 Publication of SI1527047T1 publication Critical patent/SI1527047T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)

SI200332162T 2002-07-24 2003-07-18 z N metil piperazin il metilkarbonil N metil amino anilino fenil metilen metoksikarbonil indolinon monoetansulfonat in njegova uporaba kot farmacevtski sestavek SI1527047T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10233500A DE10233500A1 (de)	2002-07-24	2002-07-24	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
EP03766212A EP1527047B1 (en)	2002-07-24	2003-07-18	3-z- 1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-me thyl-amino)-anilino)-1-phenyl-methylene -6-methoxycarbonyl-2 -indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
PCT/EP2003/007822 WO2004013099A1 (en)	2002-07-24	2003-07-18	3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition

Publications (1)

Publication Number	Publication Date
SI1527047T1 true SI1527047T1 (sl)	2012-07-31

Family

ID=30469050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200332162T SI1527047T1 (sl)	2002-07-24	2003-07-18	z N metil piperazin il metilkarbonil N metil amino anilino fenil metilen metoksikarbonil indolinon monoetansulfonat in njegova uporaba kot farmacevtski sestavek

Country Status (35)

Country	Link
US (2)	US7119093B2 (sl)
EP (2)	EP1527047B1 (sl)
JP (1)	JP5039279B2 (sl)
KR (1)	KR101145691B1 (sl)
CN (1)	CN100351235C (sl)
AR (2)	AR040662A1 (sl)
AT (1)	ATE551322T1 (sl)
AU (1)	AU2003254376B2 (sl)
BR (1)	BRPI0312811B8 (sl)
CA (1)	CA2493310C (sl)
CY (1)	CY1112916T1 (sl)
DE (1)	DE10233500A1 (sl)
DK (1)	DK1527047T3 (sl)
EA (1)	EA008684B1 (sl)
EC (1)	ECSP055571A (sl)
EG (1)	EG24562A (sl)
ES (1)	ES2384968T3 (sl)
HR (1)	HRP20050070B1 (sl)
IL (2)	IL166405A0 (sl)
ME (1)	ME00353B (sl)
MX (1)	MXPA04012785A (sl)
MY (1)	MY136883A (sl)
NO (1)	NO330486B1 (sl)
NZ (1)	NZ538367A (sl)
PE (1)	PE20040704A1 (sl)
PL (1)	PL223758B1 (sl)
PT (1)	PT1527047E (sl)
RS (1)	RS52283B (sl)
SA (1)	SA03240446B1 (sl)
SI (1)	SI1527047T1 (sl)
TW (1)	TWI285635B (sl)
UA (1)	UA78352C2 (sl)
UY (1)	UY27904A1 (sl)
WO (1)	WO2004013099A1 (sl)
ZA (1)	ZA200409814B (sl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10233500A1 (de) *	2002-07-24	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) *	2002-08-16	2004-10-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) *	2005-11-15	2007-05-24	Boehringer Ingelheim International Gmbh	Treatment of cancer
EP1870400A1 (en) *	2006-06-08	2007-12-26	Boehringer Ingelheim Pharma GmbH & Co. KG	Salts and crystalline salt forms of an 2-indolinone derivative
EP2170827B1 (en)	2007-06-21	2013-08-14	Janssen Pharmaceutica, N.V.	Indolin-2-ones and aza-indolin-2-ones
RU2525114C2 (ru)	2007-12-03	2014-08-10	Бёрингер Ингельхайм Интернациональ Гмбх	Способ получения производного индолинона
PE20091445A1 (es) *	2007-12-03	2009-10-19	Boehringer Ingelheim Int	Derivados de indolinona y procedimiento para su fabricacion
EP2985025B1 (en) *	2008-06-06	2018-01-17	Boehringer Ingelheim International Gmbh	Pharmaceutical combination
NO2299987T3 (sl) *	2008-06-06	2018-07-21
US20170065529A1 (en)	2015-09-09	2017-03-09	Boehringer Ingelheim International Gmbh	Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) *	2008-06-06	2015-01-26		Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
WO2010081817A1 (en)	2009-01-14	2010-07-22	Boehringer Ingelheim International Gmbh	Method for treating colorectal cancer
US8802384B2 (en)	2009-03-12	2014-08-12	Boehringer Ingelheim International Gmbh	Method or system using biomarkers for the monitoring of a treatment
WO2010130758A1 (en) *	2009-05-14	2010-11-18	Boehringer Ingelheim International Gmbh	New combination therapy in treatment of cancer and fibrotic diseases
EP2429520A1 (en)	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en)	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en)	2010-11-19	2012-05-24	Ratiopharm Gmbh	Intedanib salts and solid state forms thereof
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
WO2014012859A1 (en)	2012-07-19	2014-01-23	Boehringer Ingelheim International Gmbh	Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
HK1214830A1 (zh)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	新型ntrk1融合分子及其应用
EP4223770A3 (en)	2012-11-05	2023-10-18	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
EP3939614A1 (en)	2013-01-18	2022-01-19	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
US20140350022A1 (en)	2013-05-10	2014-11-27	Boehringer Ingelheim International Gmbh	Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) *	2013-06-05	2016-03-30	四川大学	吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) *	2013-07-18	2015-01-22	Concert Pharmaceuticals, Inc.	Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US20150044288A1 (en)	2013-07-31	2015-02-12	Windward Pharma, Inc.	Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20170114323A1 (en) *	2014-06-19	2017-04-27	Whitehead Institute For Biomedical Research	Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) *	2015-03-13	2016-10-12	正大天晴药业集团股份有限公司	尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) *	2015-05-06	2016-11-10	Suven Life Sciences Limited	Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) *	2015-07-13	2018-01-23	淮海工学院	固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) *	2015-07-24	2015-10-28	南京正大天晴制药有限公司	一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) *	2015-08-13	2017-02-22	南京华威医药科技开发有限公司	尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) *	2015-11-03	2017-05-11	Mylan Laboratories Limited	An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) *	2016-02-24	2017-09-06	Zentiva, K.S.	Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
JP2019511547A (ja) *	2016-04-13	2019-04-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ
EP3246029A1 (en)	2016-05-19	2017-11-22	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CN109415314A (zh) *	2016-05-19	2019-03-01	上海诚妙医药科技有限公司	尼达尼布的新晶型及其制备方法及其用途
WO2017203027A1 (en)	2016-05-27	2017-11-30	Boehringer Ingelheim International Gmbh	Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en)	2016-06-01	2017-12-07	Boehringer Ingelheim International Gmbh	Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
ITUA20164213A1 (it) *	2016-06-08	2017-12-08	Olon Spa	Polimorfo di nintedanib
US10772885B2 (en)	2016-09-26	2020-09-15	Reyoung (Suzhou) Biology Science & Technology Co., Ltd.	Composition for treating ocular diseases and methods of usage and making
JP2019536812A (ja)	2016-12-12	2019-12-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
US10981896B2 (en) *	2017-03-02	2021-04-20	Board Of Regents, The University Of Texas System	Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN110072849A (zh) *	2017-03-14	2019-07-30	新源生物科技股份有限公司	3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
TWI632133B (zh) *	2017-03-15	2018-08-11	新源生物科技股份有限公司	３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
TWI676617B (zh) *	2017-03-15	2019-11-11	新源生物科技股份有限公司	3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
JP2020512364A (ja)	2017-03-28	2020-04-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	筋ジストロフィーの処置方法において使用するためのニンテダニブ
WO2019048974A1 (en) *	2017-09-06	2019-03-14	Glenmark Pharmaceuticals Limited	Process for the preparation of nintedanib
RS67241B1 (sr)	2017-10-23	2025-10-31	Boehringer Ingelheim Int	Nova kombinacija aktivnih agensa za lečenje progresivnih fibroznih intersticijalnih bolesti pluća (pf-ild)
CN111465594B (zh)	2017-11-17	2023-11-07	费米有限公司	已知作为制备尼达尼布中间体的2-吲哚满酮的合成
PE20201502A1 (es)	2018-03-07	2020-12-29	Pliant Therapeutics Inc	Compuestos de aminoacidos y metodos de uso
EP3806858A4 (en)	2018-06-15	2022-03-09	Handa Pharmaceuticals, Inc.	KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
CN109988094B (zh) *	2019-04-29	2020-04-14	石药集团中奇制药技术（石家庄）有限公司	一种乙磺酸尼达尼布的制备方法
EP4069227A1 (en)	2019-12-04	2022-10-12	Idorsia Pharmaceuticals Ltd	Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
CN115361950A (zh)	2020-04-01	2022-11-18	勃林格殷格翰国际有限公司	生物标记物在治疗纤维化病症中的用途
US20230181582A1 (en)	2020-05-22	2023-06-15	Qx Therapeutics Inc.	Compositions and methods for treating lung injuries associated with viral infections
US20240051920A1 (en) *	2020-08-07	2024-02-15	Bdr Lifesciences Private Limited	An improved highly efficient process for the preparation of nintedanib and pharmaceutically acceptable salt thereof
CN111848490B (zh) *	2020-08-24	2021-09-24	江西国药有限责任公司	一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) *	2021-03-28	2021-06-25	郑州大学	尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en)	2021-05-31	2022-12-07	Lotus Pharmaceutical Co., Ltd.	Formulation of nintedanib
EP4486326A1 (en)	2022-02-28	2025-01-08	Nuformix Technologies Limited	Compositions and methods for treatment of idiopathic pulmonary fibrosis
JP2025525881A (ja)	2022-08-16	2025-08-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	眼内使用するためのニンテダニブの医薬製剤
KR20240042322A (ko)	2022-09-23	2024-04-02	삼아제약 주식회사	티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물
EP4578443A1 (en)	2023-12-27	2025-07-02	Faran S.A.	Oral suspensions comprising nintedanib esylate
KR20250118711A (ko)	2024-01-30	2025-08-06	삼아제약 주식회사	티로신 키나제 저해제를 유효성분으로 하는 생체이용률이 개선된 경구투여용 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB395546A (en)	1931-10-12	1933-07-20	Robert Pauli Scherer	Method of and apparatus for making capsules
US2720463A (en)	1950-11-17	1955-10-11	American Cyanamid Co	Gelatin capsule casting composition preparation
US2870062A (en)	1956-04-27	1959-01-20	Scherer Corp R P	Gelatin composition for capsules
EP0169398B1 (de)	1984-07-24	1990-08-29	R.P. Scherer GmbH	Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
GB9718913D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
DE19816624A1 (de) *	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7067513B1 (en) *	1999-08-23	2006-06-27	Solvay Pharmaceuticals B.V.	Phenylpiperazines
US6762180B1 (en) *	1999-10-13	2004-07-13	Boehringer Ingelheim Pharma Kg	Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) *	1999-10-13	2006-03-15	Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг	Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) *	1999-10-13	2001-04-19	Boehringer Ingelheim Pharma	In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10117204A1 (de)	2001-04-06	2002-10-10	Boehringer Ingelheim Pharma	In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10233500A1 (de) *	2002-07-24	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

2002
- 2002-07-24 DE DE10233500A patent/DE10233500A1/de not_active Withdrawn
2003
- 2003-07-18 UA UAA200501637A patent/UA78352C2/uk unknown
- 2003-07-18 RS YU20050046A patent/RS52283B/sr unknown
- 2003-07-18 IL IL16640503A patent/IL166405A0/xx unknown
- 2003-07-18 BR BRPI0312811A patent/BRPI0312811B8/pt active IP Right Grant
- 2003-07-18 AU AU2003254376A patent/AU2003254376B2/en active Active
- 2003-07-18 WO PCT/EP2003/007822 patent/WO2004013099A1/en not_active Ceased
- 2003-07-18 CA CA2493310A patent/CA2493310C/en not_active Expired - Lifetime
- 2003-07-18 SI SI200332162T patent/SI1527047T1/sl unknown
- 2003-07-18 KR KR1020057001207A patent/KR101145691B1/ko not_active Expired - Lifetime
- 2003-07-18 AT AT03766212T patent/ATE551322T1/de active
- 2003-07-18 MX MXPA04012785A patent/MXPA04012785A/es active IP Right Grant
- 2003-07-18 PL PL372996A patent/PL223758B1/pl unknown
- 2003-07-18 EA EA200500146A patent/EA008684B1/ru active Protection Beyond IP Right Term
- 2003-07-18 DK DK03766212.9T patent/DK1527047T3/da active
- 2003-07-18 JP JP2004525239A patent/JP5039279B2/ja not_active Expired - Lifetime
- 2003-07-18 ME MEP-2008-537A patent/ME00353B/me unknown
- 2003-07-18 CN CNB038175304A patent/CN100351235C/zh not_active Ceased
- 2003-07-18 NZ NZ538367A patent/NZ538367A/en not_active IP Right Cessation
- 2003-07-18 PT PT03766212T patent/PT1527047E/pt unknown
- 2003-07-18 EP EP03766212A patent/EP1527047B1/en not_active Expired - Lifetime
- 2003-07-18 HR HRP20050070AA patent/HRP20050070B1/hr not_active IP Right Cessation
- 2003-07-18 ES ES03766212T patent/ES2384968T3/es not_active Expired - Lifetime
- 2003-07-18 EP EP11172210A patent/EP2386543A1/en not_active Withdrawn
- 2003-07-21 US US10/623,971 patent/US7119093B2/en not_active Expired - Lifetime
- 2003-07-22 MY MYPI20032748A patent/MY136883A/en unknown
- 2003-07-22 EG EG2003070712A patent/EG24562A/xx active
- 2003-07-22 PE PE2003000728A patent/PE20040704A1/es active IP Right Grant
- 2003-07-23 AR AR20030102633A patent/AR040662A1/es not_active Application Discontinuation
- 2003-07-23 TW TW092120101A patent/TWI285635B/zh active
- 2003-07-23 UY UY27904A patent/UY27904A1/es not_active Application Discontinuation
- 2003-12-16 SA SA03240446A patent/SA03240446B1/ar unknown
2004
- 2004-12-03 ZA ZA200409814A patent/ZA200409814B/xx unknown
2005
- 2005-01-20 IL IL166405A patent/IL166405A/en active IP Right Grant
- 2005-01-24 EC EC2005005571A patent/ECSP055571A/es unknown
- 2005-02-23 NO NO20050985A patent/NO330486B1/no not_active IP Right Cessation
2006
- 2006-07-28 US US11/460,677 patent/US20060258681A1/en not_active Abandoned
2012
- 2012-06-13 CY CY20121100538T patent/CY1112916T1/el unknown
2013
- 2013-12-20 AR ARP130104954A patent/AR094217A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
BRPI0312811B1 (pt)	2019-03-12
AR094217A2 (es)	2015-07-15
EA200500146A1 (ru)	2005-08-25
RS52283B (sr)	2012-10-31
MEP53708A (en)	2011-05-10
AU2003254376A1 (en)	2004-02-23
JP2005535684A (ja)	2005-11-24
EG24562A (en)	2009-10-25
KR101145691B1 (ko)	2012-05-25
US20060258681A1 (en)	2006-11-16
ATE551322T1 (de)	2012-04-15
HRP20050070B1 (hr)	2013-09-30
AR040662A1 (es)	2005-04-13
US20040176392A1 (en)	2004-09-09
HK1078851A1 (zh)	2006-03-24
EA008684B1 (ru)	2007-06-29
ES2384968T3 (es)	2012-07-16
SA03240446B1 (ar)	2007-07-31
EP2386543A1 (en)	2011-11-16
ECSP055571A (es)	2005-04-18
RS20050046A (sr)	2007-09-21
ME00353B (me)	2011-10-10
CN1671660A (zh)	2005-09-21
PE20040704A1 (es)	2004-11-29
AU2003254376B2 (en)	2010-06-17
PL372996A1 (en)	2005-08-08
WO2004013099A1 (en)	2004-02-12
PL223758B1 (pl)	2016-10-31
UA78352C2 (uk)	2007-03-15
MXPA04012785A (es)	2005-06-08
NO330486B1 (no)	2011-04-26
TW200409754A (en)	2004-06-16
BRPI0312811B8 (pt)	2021-05-25
IL166405A0 (en)	2006-01-15
ZA200409814B (en)	2006-02-22
EP1527047A1 (en)	2005-05-04
IL166405A (en)	2009-11-18
JP5039279B2 (ja)	2012-10-03
EP1527047B1 (en)	2012-03-28
NZ538367A (en)	2008-01-31
CA2493310A1 (en)	2004-02-12
BR0312811A (pt)	2005-04-19
PT1527047E (pt)	2012-06-28
CA2493310C (en)	2011-01-18
MY136883A (en)	2008-11-28
US7119093B2 (en)	2006-10-10
CY1112916T1 (el)	2016-04-13
KR20050042139A (ko)	2005-05-04
DE10233500A1 (de)	2004-02-19
TWI285635B (en)	2007-08-21
UY27904A1 (es)	2004-02-27
DK1527047T3 (da)	2012-07-16
CN100351235C (zh)	2007-11-28
HRP20050070A2 (en)	2005-12-31
NO20050985L (no)	2005-02-23
BRPI0312811A8 (pt)	2019-01-02

Publication	Publication Date	Title
SI1527047T1 (sl)	2012-07-31	z N metil piperazin il metilkarbonil N metil amino anilino fenil metilen metoksikarbonil indolinon monoetansulfonat in njegova uporaba kot farmacevtski sestavek
DE60315892D1 (de)	2007-10-04	Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
ATE381335T1 (de)	2008-01-15	2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE438639T1 (de)	2009-08-15	2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DK1545662T3 (da)	2020-05-25	Lægemiddelindgivelsessystem
ATE382611T1 (de)	2008-01-15	Piperazin mit or-substituierter phenylgruppe und deren verwendung als glyt1-inhibitoren
DE602004032276D1 (de)	2011-05-26	Tetrahydro-Naphthalen und Harnstoffderivate
ATE430145T1 (de)	2009-05-15	3-ä(2-ä 4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü -propionsäure- ethylester -methansulfonat und dessen verwendung als arzneimittel
DE60138768D1 (de)	2009-07-02	Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
BRPI0508259A (pt)	2007-07-31	derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
DE10251294B4 (de)	2007-05-16	Polyamidformmasse und deren Verwendung
DE60318733D1 (de)	2008-03-06	Substituierte benzoxazinones und ihre verwendung
DE50206476D1 (de)	2006-05-24	Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
ATE371653T1 (de)	2007-09-15	Benzoxazinderivate und deren verwendungen
ATE342265T1 (de)	2006-11-15	Neue prodrugs von 1-methyl-2-(4- amidinophenylaminomethyl)-benzimidazol-5-yl- carbonsäure-(n -2-pyridil-n-2- hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
DE60336720D1 (de)	2011-05-26	Fluorsulfate von hexafluorisobutylen und dessen höheren homologen und deren derivaten
DE60322926D1 (de)	2008-09-25	Photopolymerisierbare zusammensetzung und verwendung davon
DK1467750T3 (da)	2006-11-13	Orodispergerbar farmaceutisk sammensætning omfattende perindopril
EP1476176A4 (en)	2006-02-22	TRANSPORT PEPTIDES AND USES THEREOF
ATE494278T1 (de)	2011-01-15	Anthranilsäureamide und ihre pharmazeutische verwendung
ATE555097T1 (de)	2012-05-15	4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
ATE372342T1 (de)	2007-09-15	Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
DE60331160D1 (de)	2010-03-18	Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva
ATE443512T1 (de)	2009-10-15	Pharmazeutische zusammensetzung von piperazinderivaten
DK1653963T3 (da)	2007-04-10	Nasal farmaceutisk sammensætning piribedil